Essential Thrombocythemia - Pipeline Review, Q1 2011

Global Markets Direct, January 2011, Pages: 21

Essential Thrombocythemia - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Essential Thrombocythemia - Pipeline Review, Q1 2011', provides an overview of the Essential Thrombocythemia therapeutic pipeline. This report provides information on the therapeutic development for Essential Thrombocythemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia. 'Essential Thrombocythemia - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Essential Thrombocythemia.
- A review of the Essential Thrombocythemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Essential Thrombocythemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Essential Thrombocythemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Essential Thrombocythemia pipeline depth and focus of Essential Thrombocythemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Essential Thrombocythemia Overview
Therapeutics Development
An Overview of Pipeline Products for Essential Thrombocythemia
Essential Thrombocythemia Therapeutics under Development by Companies
Companies Involved in Essential Thrombocythemia Therapeutics Development
YM BioSciences Inc.
Novartis AG
Cephalon, Inc.
S-BIO Pte Ltd
Essential Thrombocythemia Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Essential Thrombocythemia - Featured News
Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting
Mar 03, 2010: Geron Gives Five Presentations On Telomerase Inhibitor Imetelstat At The AACR Annual Meeting
May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Essential Thrombocythemia, 2011
Products under Development for Essential Thrombocythemia – Comparative Analysis, 2011
YM BioSciences Inc., 2011
Novartis AG, 2011
Cephalon, Inc., 2011
S-BIO Pte Ltd, 2011
Assessment by Monotherapy Products, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011

List of Figures
Number of Products under Development for Essential Thrombocythemia, 2011
Products under Development for Essential Thrombocythemia – Comparative Analysis, 2011
Products under Development by Companies, 2011
Assessment by Monotherapy Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011

Customers who bought this item also bought

• Essential Thrombocythemia – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Bone Marrow Transplantation – Pipeline Review, H1 2013
• Peanut Allergy – Pipeline Review, H1 2013
• Community-Acquired Infections – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Contraceptives – Pipeline Review, H1 2013